0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Recombinant plasminogen agent continues to show promise in trials

Marsha F. Goldsmith
JAMA. 1985;253(12):1693-1694. doi:10.1001/jama.1985.03350360017001.
Text Size: A A A
Published online

ABSTRACT

Results of the first multicenter clinical trial of recombinant human tissue-type plasminogen activator have taken the thrombolytic protein "out of the speculative pilot phase and put it into the clinically useful phase."

That is the assessment of Burton E. Sobel, MD, director of cardiology at Washington University School of Medicine-Barnes Hospital Medical Center, St Louis, one of the three trial locations (JAMA [MEDICAL NEWS] 1984;251:1651-1652).

Speaking at the annual meeting of the American Heart Association in Miami Beach, Sobel said he considers the successful trial—in which intravenously injected recombinant human tissue-type plasminogen activator opened coronary arteries in 35 of 50 patients with transmural infarctions and angiographically documented coronary occlusions—"a reason for tremendous excitement." Genentech Inc, the South San Francisco, Calif, genetic engineering firm that produces recombinant human tissue-type plasminogen activator in this country, he added, "has taken a [sparsely occurring native] molecule with great potential and produced it for practical

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();